All In Biotech

Drug Trial Radar · NCT04382053

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function

Last checked: Nov 19, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

143

Actual

Start

May 27, 2020

Primary completion

Dec 10, 2020

Study completion Dec 24, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study was designed to assess the efficacy and safety of DFV890 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.

Conditions

  • COVID-19 Pneumonia, Impaired Respiratory Function

Interventions

  • DFV890Drug

    DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.

  • Standard of Care (SoC)Drug

    SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)Time frame: up to Day 15

Locations

29 sites in 12 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Hvidovre, Denmark

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    New Delhi, India

  • Novartis Investigative Site

    New Delhi, India

  • Novartis Investigative Site

    Coimbatore, Tamil Nadu, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

  • Novartis Investigative Site

    Mexico City, Mexico CP, Mexico

  • Novartis Investigative Site

    Monterrey, Nuevo León, Mexico

  • Novartis Investigative Site

    Harderwijk, Netherlands

  • Novartis Investigative Site

    San Martín de Porres, Lima region, Peru

  • Novartis Investigative Site

    San Miguel, Lima region, Peru

  • Novartis Investigative Site

    Barnaul, Russia

  • Novartis Investigative Site

    Chelyabinsk, Russia

  • Novartis Investigative Site

    Krasnoyarsk, Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Ryazan, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Yekaterinburg, Russia

  • Novartis Investigative Site

    George, Western Cape, South Africa

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.